Is Buying 52-Week Stock Like Iovance Biotherapeutics, Inc. (IOVA) a Winning Strategy?

March 13, 2018 - By Darrin Black

The stock of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) hit a new 52-week high and has $19.47 target or 7.00 % above today’s $18.20 share price. The 8 months bullish chart indicates low risk for the $1.58 billion company. The 1-year high was reported on Mar, 13 by Barchart.com. If the $19.47 price target is reached, the company will be worth $110.81M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 4.96% or $0.95 during the last trading session, reaching $18.2. About 620,036 shares traded. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has 0.00% since March 13, 2017 and is . It has underperformed by 16.70% the S&P500.

More notable recent Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) news were published by: Globenewswire.com which released: “Iovance Biotherapeutics Appoints Michael Weiser, MD, Ph.D., to its Board of …” on March 01, 2018, also Globenewswire.com with their article: “Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March” published on March 07, 2018, Digitaljournal.com published: “NASDAQ:IOVA Shareholder Notice: Update in Lawsuit Against Iovance …” on March 13, 2018. More interesting news about Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) were released by: Globenewswire.com and their article: “Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and …” published on March 08, 2018 as well as Prnewswire.com‘s news article titled: “Johnson Fistel, LLP Announces Investigations of RH, WageWorks, Inc., BRF SA …” with publication date: March 07, 2018.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $1.58 billion. The companyÂ’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patientsÂ’ tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: